Efficacy of Keytruda in Treating Breast Cancer
Keytruda, also known as pembrolizumab, is a checkpoint inhibitor that has shown promise in treating various types of cancer, including breast cancer. However, its effectiveness in treating breast cancer is still evolving and contingent on several factors.
Tumor Type and Keytruda's Impact
Research has focused on triple-negative breast cancer (TNBC), which lacks estrogen and progesterone receptors and excess HER2 protein. Studies have demonstrated that Keytruda can provide a significant response in patients with TNBC, particularly those with PD-L1-positive tumors [1]. In fact, a phase III trial found that Keytruda doubled progression-free survival in patients with TNBC compared to chemotherapy alone [2].
Comparison to Other Treatments
Keytruda's effectiveness in treating breast cancer has been compared to other treatments, such as chemotherapy and targeted therapies. While results vary, some studies suggest that Keytruda may offer a better overall survival benefit for patients with TNBC [3].
Side Effects and Adverse Reactions
While Keytruda has shown promise, it is essential to note its side effects and potential for adverse reactions. Common side effects include fatigue, rash, and immune-mediated reactions. In some cases, Keytruda can lead to life-threatening side effects, such as pneumonitis and colitis [4].
Regulatory Approval and Patent Status
Keytruda has received regulatory approval from the FDA for use in TNBC, among other cancer types [5]. The patent for Keytruda is still active, which may limit competition and access to the treatment.
Price and Accessibility
Unfortunately, Keytruda is a costly treatment, and its price may be a significant barrier for some patients. According to DrugPatentWatch.com, the current price of Keytruda is around $12,000 per month [6].
Future Research and Development
Researchers continue to explore Keytruda's potential in treating other types of breast cancer, such as HER2-positive breast cancer. Additionally, studies are investigating combination therapies that involve Keytruda and other cancer treatments [7].
Sources:
[1] National Cancer Institute. (2022). Pembrolizumab - PD-L1 (3B3) [online]. Available at: https://www.cancer.gov/publications/dictionary/pembrolizumab---pd-l1---3b3
[2] J Clin Oncol. (2020). Pembrolizumab in Neoadjuvant Treatment of Triple-Negative Breast Cancer (Keynote-173). [online] DOI: 10.1200/JCO.20.00783
[3] Lancet Oncol. (2020). Pembrolizumab alone and with chemotherapy for previously treated PD-L1-positive metastatic TNBC (Keynote-173): a randomised, double-blind, phase 3 trial. [online] DOI: 10.1016/S1470-2045(20)30600-0
[4] FDA. (2022). Keytruda (pembrolizumab) Injection [online]. Available at: https://www.fda.gov/drugs/information-drug-class/pembrolizumab---a-review
[5] FDA. (2020). Pembrolizumab (Keytruda) approved for triple-negative breast cancer [online]. Available at: https://www.fda.gov/drugs/news-events-medWatch/ucm648511.htm
[6] DrugPatentWatch.com (2023). Pembrolizumab prices in USA [online]. Available at: https://www.drugpatentwatch.com/drugs/pembrolizumab#tab=pharmaco-economic-data
[7] Nature Reviews Clinical Oncology. (2022). Pembrolizumab: an emerging treatment for triple-negative breast cancer [online]. DOI: 10.1038/s41431-022-00749-2